Press Releases
Biocon Inks Co-Development & Commercialization Agreement with Lab PiSA for rh- Insulin in USA
Biocon Ltd. (BSE code: 532523, NSE: BIOCON) Asia's premier biopharmaceuticals company, announced today that its wholly owned subsidiary Biocon SA has entered into an...
News
Dr. Reddy’s and TR-Pharm Announce Strategic Collaboration in Turkey
Reddy’s Laboratories Ltd. and TR-Pharm announced a strategic collaboration agreement involving 3 biosimilar products. A total of three products will be registered and subsequently...
Press Releases
Scripps Florida Scientists Win $1.4 Million Grant to Develop New Ways to Block Breast Cancer
AbbVie and Boehringer Ingelheim announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for...
Press Releases
ModiQuest Research and Sobi™ to Continue their Collaboration on Antibody Generation
The Dutch antibody services company, today announced that it will continue its collaboration with Sobi™ aimed at the generation of novel monoclonal antibodies against...
News
Teva Receives European Commission Approval for the Allergan Generics Acquisition
Teva Pharmaceutical Industries Ltd. announced that it has received regulatory approval from the European Commission for its acquisition of Allergan plc’s global generics business....
News
Takeda and Frazier Healthcare Partners to Develop New Therapeutics in Urology and Gynecology
Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners today announced the formation of Outpost Medicine, a biopharmaceutical company focused on the development of new...
Research Insight
FDA approves new indication for Novartis drug Afinitor
Novartis announced that the United States Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read















